X-ray computed tomography (CT) has an important role in precision medicine. X-ray computed tomography (CT) relies on iodinated contrast agents, yet clinical small-molecule agents suffer from rapid clearance and a toxicological coupling between iodine concentration and osmolality. In addition, CT contrast agents with high efficiency and the ability to translate diagnostic accuracy into therapeutic intervention are scarce. Here, poly(diiododiacetylene) (PIDA), a conjugated polymer composed of only carbon and iodine atoms, is reported as an efficient CT contrast agent to bridge CT diagnostic imaging with therapeutic intervention. PIDA has a high iodine payload (>84 wt%), and the aggregation of nanofibrous PIDA can further amplify CT intensity and has improved geometrical and positional stability in vivo. Moreover, with a conjugated backbone, PIDA has an ultrastrong Raman scattering intensity, which is over 5 magnitudes higher than conventional small Raman probe. The strong CT and Raman signaling of PIDA make it dually visible by both CT imaging and Raman imaging. The performance of PIDA in CT-guided preoperative planning and visualization-guided surgery is validated using orthotopic xenograft rat models. In addition, PIDA excels clinical fiducial markers of imaging-guided radiotherapy in efficiency and biocompatibility, and exhibits successful guidance of robotic radiotherapy on Beagles, demonstrating clinical potential to translate CT diagnosis accuracy into therapeutic intervention for precision medicine.